RT Journal Article
T1 Long-term virological suppression on first-line efavirenz plus tenofovir=emtricitabine/lamivudine for HIV-1
A1 Stirrup, Oliver
A1 Sterne, Jonathan
A1 Dunn, David T.
A1 Grabmeier-Pfistershammer, Katharina
A1 Papastamopoulos, Vasileios
A1 Vandenhende, Marie-Anne
A1 Wit, Ferdinand
A1 Porter, Kholoud
A1 Gunsenheimer-Bartmeyer, Barbara
A1 Jarrin, Inma
A1 Garcia, Federico
A1 Faetkenheuer, Gerd
A1 Obel, Niels
A1 Schultze, Anna
A1 Antinori, Andrea
A1 Ceccherini-Silberstein, Francesca
A1 Mussini, Cristina
A1 Chene, Genevieve
A1 Neesgaard, Bastian
A1 Castagna, Antonella
A1 Kouyos, Roger
A1 De Wit, Stephane
A1 Sonnerbor, Anders
A1 Sabin, Caroline
A1 Merino, Dolores
A1 Barger, Diana
A1 Phillips, Andrew
A1 COHERE EuroCoord, 
K1 antiretroviral therapy
K1 viral failure
K1 viral rebound
K1 viral suppression
K1 virological control
K1 Antiretroviral therapy
K1 Viral load
K1 Durability
K1 Infection
K1 Efficacy
K1 Failure
AB Objectives: Evaluate long-term rates of virological failure and treatment interruption for people living with HIV (PLWHIV) with viral suppression on first-line efavirenz+tenofovir disoproxil fumarate+emtricitabine/lamivudine (EFV+TDF+FTC/3TC), and compare these according to patient characteristics.Methods: PLWHIV enrolled in the Collaboration of Observational HIV Epidemiological Research Europe cohort collaboration, who started first-line EFV+TDF+FTC/3TC at age at least 16 years and had viral suppression (= 200 copies/ml) and (complete) treatment interruption were estimated according to years since initial suppression. We used Poisson regression to examine associations of baseline characteristics with rates of virological failure or treatment interruption.Results: Among 19 527 eligible PLWHIV with median (interquartile range) follow-up 3.7 (2.0-5.6) years after initial viral suppression, the estimated rate of the combined incidence of virological failure or treatment interruption fell from 9.0/100 person-years in the first year to less than 4/100 person-years beyond 3 years from suppression; considering only those remaining on EFV+TDF+FTC/3TC, the combined rate dropped from 8.2/100 person-years in the first year to less than 3.5/100 person-years beyond 3 years. PLWHIV with injecting drug-related or heterosexual transmission were at higher risk of virological failure or treatment interruption, as were those of Black ethnicity. PLWHIV aged less than 35 years were at higher risk of virological failure and treatment interruption.Conclusion: PLWHIV starting first-line EFV+TDF+FTC/3TC had low rates of virological failure and treatment interruption up to 10 years from initial suppression. Demographic characteristics can be used to identify subpopulations with higher risks of these outcomes. Copyright (C) 2019 The Author(s). Published by Wolters Kluwer Health, Inc.
PB Lippincott williams & wilkins
SN 0269-9370
YR 2019
FD 2019-03-15
LK https://hdl.handle.net/10668/26140
UL https://hdl.handle.net/10668/26140
LA en
DS RISalud
RD Apr 7, 2025